TXG240517P20000
- 0.20
- 0.000.00%
10x Genomics Newsroom
10x Genomics Stock Slides Amid German Patent Court Ruling
Express News | German Federal Patent Court Invalidates European Patent No. 2794928b1 In Germany
German Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win To NanoString, Now A Bruker Business, Will Seek An End To The Injunction Impacting Sales Of CosMx SMI Products In Germany
NanoString, now a Bruker business, will promptly seek an end to the injunction impacting sales of CosMx SMI products in GermanyBruker Corporation (NASDAQ:BRKR) today announced that the German Federal
Express News | Bruker Corp - German Federal Patent Court Invalidates Patent Asserted by 10X Genomics
Express News | 10X Genomics Inc : Stephens Cuts Target Price to $45 From $62
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), 10x Genomics (TXG) and LivaNova (LIVN)
10x Genomics First Quarter 2024 Earnings: In Line With Expectations
Insider Moves Spark Speculation: 10X Genomics Executives Rethink Stock Sale Strategies
UBS Adjusts 10x Genomics Price Target to $30 From $52, Maintains Neutral Rating
10x Genomics (TXG) has an average rating of outperform and price targets ranging from $26 to $62, according to analysts polled by Capital IQ. Price: 26.91, Change: -2.37, Percent Change: -8.09
10x Genomics Price Target Cut to $32.00/Share From $57.00 by TD Cowen
10x Genomics Price Target Cut to $32.00/Share From $57.00 by TD Cowen
10x Genomics Is Maintained at Buy by Stifel
10x Genomics Is Maintained at Buy by Stifel
Express News | Stifel Maintains Buy on 10x Genomics, Lowers Price Target to $53
10x Genomics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 105.43% Stifel $63 → $53 Maintains Buy 04/29/2024 93.8% Canaccord Genuity $65 → $50 Maintains B
Express News | 10X Genomics Inc : TD Cowen Cuts to Hold From Buy
Earnings Call Summary | 10x Genomics(TXG.US) Q1 2024 Earnings Conference
The following is a summary of the 10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript:Financial Performance:10x Genomics reported Q1 total revenue growth of 5% to $141 million.Consumption revenu
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)
Express News | 10X Genomics Inc : JP Morgan Cuts Target Price to $40 From $65
Analysts' Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)
The European Unified Patent Court Clears Curio Seeker With Respect To Claim 1 Of EP 2697391 Asserted By 10x Genomics
The European Unified Patent Court (UPC) today announced a finding that Curio Seeker does not infringe main claim 1 of EP 2697391 asserted by 10x Genomics (NASDAQ:TXG). The UPC has also ordered Curio B
10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...